Quest Diagnostics (DGX) – StreetInsider.com Reports
-
Quest Diagnostics (DGX) PT Raised to $145 at Evercore ISI
-
Quest Diagnostics (DGX) Tops Q1 EPS by 18c, Beats on Revenue; Offers FY24 Guidance
-
Quest Diagnostics (DGX) PT Lowered to $135 at Baird
-
Leerink Partners Starts Quest Diagnostics (DGX) at Market Perform
-
Jefferies Upgrades Quest Diagnostics (DGX) to Buy, 'Guidance Is Attainable, M&A To Drive Upside, Valuation's Compelling'
-
Quest Diagnostics (DGX) PT Lowered to $150 at BofA Securities
-
Quest Diagnostics (DGX) PT Lowered to $125 at Deutsche Bank
-
Quest Diagnostics (DGX) PT Lowered to $145 at Truist Securities
-
Quest Diagnostics (DGX) PT Lowered to $150 at Mizuho Securities
-
Quest Diagnostics (DGX) PT Lowered to $136 at Baird
-
Quest Diagnostics (DGX) PT Lowered to $138 at Barclays
-
Quest Diagnostics (DGX) Tops Q4 EPS by 4c, Beats on Revenue; Offers FY24 Guidance
-
Quest Diagnostics (DGX) Raises Quarterly Dividend 5.6% to $0.75; 2.3% Yield
-
Quest Diagnostics (DGX) PT Lowered to $152 at JPMorgan
-
Quest Diagnostics (DGX) PT Raised to $144 at Baird
-
Quest Diagnostics (DGX) Acquires Select Assets of Outreach Lab Services Business of Steward Health Care System
-
Barclays Starts Quest Diagnostics (DGX) at Equalweight
-
Quest Diagnostics (DGX) Appoints Yuri A. Fesko as Chief Medical Officer
-
Quest Diagnostics (DGX) PT Raised to $150 at Truist Securities
-
Quest Diagnostics (DGX) Launches New 88-Compound Novel Psychoactive Substance Test Panel
-
Quest Diagnostics (DGX) PT Raised to $153 at JPMorgan
-
BofA Securities Upgrades Quest Diagnostics (DGX) to Buy, 'Growth at a reasonable price'
-
Quest Diagnostics (DGX) PT Raised to $145 at Citi
-
Quest Diagnostics (DGX) PT Raised to $137 at UBS
-
Quest Diagnostics (DGX) and Scipher Medicine Collaborate to Scale Precision Medicine Access for Patients with Rheumatoid Arthritis
-
Quest Diagnostics (DGX) and Universal DX Collaborate to Bring Advanced Colorectal Cancer Screening Blood Test to Patients and Providers in the US
-
Quest Diagnostics (DGX) PT Raised to $149 at JPMorgan
-
Quest Diagnostics (DGX) PT Raised to $145 at Morgan Stanley
-
Quest Diagnostics (DGX) Declares $0.71 Quarterly Dividend; 2.1% Yield
-
Quest Diagnostics (DGX) Launches Mobile Phlebotomy Service
-
Quest Diagnostics (DGX) Prices $750M Notes Offering
-
Quest Diagnostics (DGX) PT Lowered to $140 at Baird
-
Quest Diagnostics (DGX) PT Lowered to $145 at Truist Securities
-
Quest Diagnostics (DGX) and Diadem SpA Enter Exclusive U.S. Licensing Agreement for AlzoSure Predict Alzheimer's Disease Prognostic Technology
-
Quest Diagnostics (DGX) PT Lowered to $130 at Citi
-
Quest Diagnostics (DGX) Tops Q3 EPS by 3c; raises guidance
-
Quest Diagnostics (DGX) PT Lowered to $135 at UBS
-
Quest Diagnostics (DGX) PT Raised to $145 at Piper Sandler
-
Quest Diagnostics (DGX) PT Raised to $151 at Baird
-
Quest Diagnostics (DGX) PT Lowered to $136 at Evercore ISI
-
Quest Diagnostics (DGX) granted Breakthrough Device Designation from FDA for AAV test
-
Quest Diagnostics (DGX) Declares $0.71 Quarterly Dividend; 2.1% Yield
-
Walmart, Chevron, Adobe rise premarket; Johnson&Johnson, Carvana fall
-
Quest Diagnostics (DGX) Introduces First-To-Market Consumer-Initiated Blood Test for Alzheimer's Disease Risk Assessment on questhealth.com
-
Quest Diagnostics (DGX) PT Raised to $148 at JPMorgan
-
Quest Diagnostics (DGX) PT Lowered to $155 at Truist Securities
-
Quest Diagnostics (DGX) Tops Q2 EPS by 2c; beats on guidance
-
Quest Diagnostics (DGX) PT Raised to $149 at Baird
-
Piper Sandler Starts Quest Diagnostics (DGX) at Neutral
-
Quest Diagnostics (DGX) PT Lowered to $140 at Evercore ISI
Back to DGX Stock Lookup